[1] Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia. J Hepatol,2017,67(4):862-873. [2] Perumpail BJ,Khan MA,Yoo ER,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol,2017,23(47):8263-8276. [3] 马振增,陆伦根. 非酒精性脂肪性肝病与肝硬化. 实用肝脏病杂志,2016(2):135-138. [4] de Medeiros IC,de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease-A mechanistic hypothesis. Med Hypoth,2015,85(2):148-152. [5] Eslam M,Valenti L,Romeo S.Genetics and epigenetics of NAFLD and NASH:Clinical impact. J Hepatol,2018,68(2):268-279. [6] Del C J,Gallego-Duran R,Gallego P,et al.Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci,2018,19(3):334-338. [7] Chen CH,Ferreira JC,Gross ER,et al.Targeting aldehyde dehydrogenase 2:new therapeutic opportunities. Physiol Rev,2014,94(1):1-34. [8] Zhu Y,Zhang D,Zhou D,et al.Susceptibility loci for metabolic syndrome and metabolic components identified in Han Chinese:a multi-stage genome-wide association study. J Cell Mol Med,2017,21(6):1106-1116. [9] Younossi Z,Anstee QM,Marietti M,et al.Global burden of NAFLD and NASH:trends,predictions,risk factors and prevention. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20. [10] de Ledinghen V,Vergniol J,Capdepont M,et al. Controlled attenuation parameter(CAP) for the diagnosis of steatosis:a prospective study of 5323 examinations. J Hepatol,2014,60(5): 1026-1031. [11] de Ledinghen V,Wong GL,Vergniol J,et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2016,31(4):848-855. [12] Shen F,Zheng R D,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol,2014,20(16):4702-4711. [13] 李岩,郝志华,陈春彦,等. 瞬时弹性成像对非酒精性脂肪性肝病的应用价值. 中国超声医学杂志,2014,20(5):414-418. [14] 李颖怡,曹海霞,汪余勤. 乙醛脱氢酶2与非酒精性脂肪性肝病相关性的研究进展. 国际消化病杂志,2018,32(1):10-15. [15] Yoshida A,Huang I Y,Ikawa M.Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A,1984,81(1):258-261. [16] Lai C L,Yao C T,Chau G Y,et al.Dominance of the inactive Asian variant over activity and protein contents of mitochondrial aldehyde dehydrogenase 2 in human liver. Alcohol Clin Exp Res,2014,38(1):44-50. [17] Li H,Toth E,Cherrington NJ.Alcohol metabolism in the progression of human nonalcoholic steatohepatitis. Toxicol Sci,2018,164(2):428-438. [18] Stachowicz A,Olszanecki R,Suski M,et al.Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. J Am Heart Assoc,2014,3(6):e1329. [19] You M,Fischer M,Deeg MA,et al.Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem,2002,277(32):29342-29347. [20] Oniki K,Morita K,Watanabe T,et al.The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease. Nutr Diabetes,2016,6:e210. |